Login to Your Account



Shire Picks Up Option for CNS Drug in $190M Heptares Deal

By Nuala Moran
Staff Writer

Wednesday, March 21, 2012
LONDON – Heptares Therapeutics Ltd. said the starting gun has been fired on a $190 million-plus-royalties deal, after Shire plc decided to take up its option on an A2A antagonist discovered by Heptares.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription